Decision curve analysis (DCA) indicated that, when the predicted probability threshold for diagnosing IDH‐mutated glioma with a p53 mutation was established at 60%, the clinical‐radiomics prediction model would result in a net benefit for 80 out of every 100 patients evaluated. This evidence concerns the gene TP53 and central nervous system cancer.